In Brief: Becton Dickinson
This article was originally published in The Gray Sheet
Executive SummaryBecton Dickinson: Work on a $25 mil. manufacturing facility has begun in southeastern China in Suzhou, Jiangsu province, the firm says. Under a joint venture agreement with Suzhou Pharmaceutical General Company announced last September, the facility will produce intravenous catheters, hypodermic needles, disposable anesthesia needles, and disposable hypodermic syringes for the Chinese and other overseas markets. The venture is Becton Dickinson's first in China...
You may also be interested in...
The US FDA has overhauled its ‘Purple Book’ to make it a searchable database of biologics information. The agency is also seeking input on next steps.
The International Council for Harmonisation has replaced its 1993 guideline on reproductive toxicity studies with an updated version.
Stada says it has become a "major consumer healthcare player" after signing a deal to acquire from GSK 15 brands, which generate annual sales of around €120m.